Abstract 1571P
Background
Cancer-related neuropathic pain (CRNP) is common but is difficult to diagnose and treat in clinical practice (Edwards et al., 2019). A European patient survey was conducted to assess the impact of CRNP on patients and whether there are any differences in pain support across the cancer journey.
Methods
An online survey, prepared, conducted and analysed with a team of experts including physicians, nurses and patients, was completed in June 2021. Adults consenting to participate and diagnosed with cancer were screened for symptoms of neuropathic pain. Respondents who met three or more of the DN4 (Douleur Neuropathique 4) criteria were enrolled and answered questions about their experiences regarding the diagnosis and management of CRNP.
Results
549 persons from 13 European countries participated in the study. Of those recruited, 88% were ≤ 65 years old, 32% experienced severe pain daily and 89% had signs and symptoms consistent with CRNP. In the presence of CRNP symptoms, 40% did not have an HCP confirmed diagnosis of neuropathic pain. The proportion of respondents in active cancer treatment was 44% (n=240) , 42% (n=232) received no active cancer treatment but were still in oncology care, 13% (n=70) were no longer in oncology care (i.e. a ‘cancer survivor’), finally 1% (n=7) were not yet in cancer treatment. Compared to those currently in active cancer treatment, cancer survivors were less likely to have a diagnosis of CRNP (69% vs 53%) or regular conversations with HCPs about their pain, received fewer pain treatments, and described feeling less support and empathy from HCPs around their pain. 82% of patients in active cancer treatment reported that they were warned by an HCP about the potential to develop neuropathic pain vs 29% of patients who were no longer in cancer care.
Conclusions
Even though CRNP has a substantial impact on patients’ lives, it remains under-recognised and especially in cancer survivors who are no longer in cancer care, special focus on pain management is needed. Reference: Edwards HL, Mulvey MR, Bennett MI. Cancer-Related Neuropathic Pain. Cancers (Basel). 2019;11(3):373.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Grünenthal GmbH.
Funding
Grünenthal GmbH.
Disclosure
D. Dupoiron: Financial Interests, Personal, Invited Speaker: Grünenthal GmbH, Medtronic, Esteve. G.M. Petersen: Financial Interests, Personal, Member: Grünenthal GmbH. M. Eerdekens: Financial Interests, Personal, Member: Grünenthal GmbH. All other authors have declared no conflicts of interest.